Mouser Electronics Announces Partnership with DS PENSKE for Formula E Season 11 with Debut in Brazil

3.12.2024 17:09:00 CET | Business Wire | Press release

Mouser Electronics, Inc., the New Product Introduction (NPI) leader™ empowering innovation, is gearing up to sponsor the DS PENSKE Formula E racing team as they begin Season 11 at the Sambadrome in São Paulo, Brazil, on December 7. Mouser is sponsoring the team throughout the 2024/2025 ABB FIA Formula E World Championship racing season in collaboration with TTI, Inc. and valued manufacturers Molex and KYOCERA AVX.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241203326874/en/

This is the first time that Brazil has hosted the Formula E season-opener, and the race will see two-time Formula E World Champion Jean-Éric Vergne joined by Maximilian Günther as they pilot the new GEN3 Evo car. The GEN3 Evo is faster, stronger, and more agile than its predecessors and features an aggressive new body kit designed to be stronger, more robust and more aerodynamic. It also allows for all-wheel drive, a first for a Formula E car.

"Mouser is thrilled to continue our support of the DS PENSKE Formula E team," said Todd McAtee, Senior Vice President, Business Development for Mouser Electronics. "We're also excited to see what the new car can do. With acceleration 0-60mph, 30% faster than a current F1 car, this is sure to be an exhilarating season."

"TTI is pleased to team up again with Mouser to support DS PENSKE and promote this dynamic sport and its commitment to innovation and environmental responsibility," said Mike Morton, TTI Chief Executive Officer. "We will be looking forward to a winning year ahead."

"The new car promises to continue the evolution of Formula E and serves as a powerful showcase for the electric future of motorsports," said Fred Bell, Molex Vice President of Global Distribution. "Mouser and Molex have been proud supporters since the inception of Formula E, and we wish the DS PENSKE team a safe and successful season."

"We're delighted to collaborate with Mouser and TTI in our partnership with the DS PENSKE Formula E racing team for another exciting season," said Alex Schenkel, KYOCERA AVX Senior Vice President of Global Sales.

Formula E will complete a 16-race season spanning ten iconic venues as it continues to pioneer all-electric racing. The globe-trotting schedule includes a return to Miami, Florida, double-headers in Tokyo and Monaco, and Formula E's first-ever trip to Jeddah in Saudi Arabia. A double-header finale in London, England, rounds out the largest Formula E race calendar to date.

Formula E cars are powered solely by electricity and represent a vision for the future of the motorsports industry, serving as a framework for research and development around zero-emission motoring. Racing is all about speed and endurance, and racing partnerships are an innovative way for Mouser to communicate its performance-driven business model and promote the newest technologies from its manufacturer partners.

To learn more about the Mouser-backed DS PENSKE Formula E racing team and view the Formula E schedule, visit https://www.mouser.com/formula-e/.

For more Mouser news and our latest new product introductions, visit https://www.mouser.com/newsroom/.

As a global authorized distributor, Mouser offers the widest selection of the newest semiconductors, electronic components and industrial automation products. Mouser's customers can expect 100% certified, genuine products that are fully traceable from each of its manufacturer partners. To help speed customers' designs, Mouser's website hosts an extensive library of technical resources, including a Technical Resource Center, along with product data sheets, supplier-specific reference designs, application notes, technical design information, engineering tools and other helpful information.

Engineers can stay abreast of today's exciting product, technology and application news through Mouser's complimentary e-newsletter. Mouser's email news and reference subscriptions are customizable to the unique and changing project needs of customers and subscribers. No other distributor gives engineers this much customization and control over the information they receive. Learn about emerging technologies, product trends and more by signing up today at https://sub.info.mouser.com/subscriber/.

About Mouser Electronics
Mouser Electronics is an authorized semiconductor and electronic component distributor focused on New Product Introductions from its leading manufacturer partners. Serving the global electronic design engineer and buyer community, the global distributor's website, mouser.com, is available in multiple languages and currencies and features more than 6.8 million products from over 1,200 manufacturer brands. Mouser offers 28 support locations worldwide to provide best-in-class customer service in local language, currency and time zone. The distributor ships to over 650,000 customers in 223 countries/territories from its 1 million-square-foot, state-of-the-art distribution facilities in the Dallas, Texas, metro area. For more information, visit https://www.mouser.com/.

Trademarks
Mouser and Mouser Electronics are registered trademarks of Mouser Electronics, Inc. All other products, logos, and company names mentioned herein may be trademarks of their respective owners.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241203326874/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom